[go: up one dir, main page]

PL2070922T3 - Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3 - Google Patents

Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3

Info

Publication number
PL2070922T3
PL2070922T3 PL08169934T PL08169934T PL2070922T3 PL 2070922 T3 PL2070922 T3 PL 2070922T3 PL 08169934 T PL08169934 T PL 08169934T PL 08169934 T PL08169934 T PL 08169934T PL 2070922 T3 PL2070922 T3 PL 2070922T3
Authority
PL
Poland
Prior art keywords
azabicyclo
dopamine
modulators
receptors
derivatives useful
Prior art date
Application number
PL08169934T
Other languages
English (en)
Inventor
Luca Arista
Giorgio Bonanomi
Anna Maria Capelli
Federica Damiani
Fabio Romano Di
Gabriella Gentile
Dieter Hamprecht
Fabrizio Micheli
Luca Tarsi
Giovanna Tedesco
Silvia Terreni
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403990A external-priority patent/GB0403990D0/en
Priority claimed from GB0404083A external-priority patent/GB0404083D0/en
Priority claimed from GB0417120A external-priority patent/GB0417120D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2070922T3 publication Critical patent/PL2070922T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08169934T 2004-02-23 2005-02-21 Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3 PL2070922T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0403990A GB0403990D0 (en) 2004-02-23 2004-02-23 Compounds
GB0404083A GB0404083D0 (en) 2004-02-24 2004-02-24 Compounds
GB0417120A GB0417120D0 (en) 2004-07-30 2004-07-30 Compounds
EP08169934A EP2070922B1 (en) 2004-02-23 2005-02-21 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
EP05707610A EP1745040B9 (en) 2004-02-23 2005-02-21 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number Publication Date
PL2070922T3 true PL2070922T3 (pl) 2012-01-31

Family

ID=34890800

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08169935T PL2060570T3 (pl) 2004-02-23 2005-02-21 Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3
PL08169934T PL2070922T3 (pl) 2004-02-23 2005-02-21 Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3
PL05707610T PL1745040T3 (pl) 2004-02-23 2005-02-21 Pochodne azabicyklo(3.1.0)heksanu użyteczne jako modulatory receptorów dopaminowych D3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08169935T PL2060570T3 (pl) 2004-02-23 2005-02-21 Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05707610T PL1745040T3 (pl) 2004-02-23 2005-02-21 Pochodne azabicyklo(3.1.0)heksanu użyteczne jako modulatory receptorów dopaminowych D3

Country Status (25)

Country Link
US (3) US7855298B2 (pl)
EP (3) EP2070922B1 (pl)
JP (1) JP4960217B2 (pl)
KR (1) KR101143718B1 (pl)
CN (1) CN1946714B (pl)
AR (1) AR047890A1 (pl)
AT (3) ATE451364T1 (pl)
AU (2) AU2005215918C1 (pl)
BR (1) BRPI0507945A (pl)
CA (1) CA2557115C (pl)
CY (3) CY1109854T1 (pl)
DE (1) DE602005018190D1 (pl)
DK (3) DK2060570T3 (pl)
ES (2) ES2337590T3 (pl)
HR (3) HRP20100114T1 (pl)
IL (1) IL177184A0 (pl)
MA (1) MA28438B1 (pl)
NO (1) NO20064309L (pl)
PE (1) PE20051173A1 (pl)
PL (3) PL2060570T3 (pl)
PT (3) PT2070922E (pl)
RU (1) RU2434011C2 (pl)
SI (3) SI1745040T1 (pl)
TW (1) TW200538113A (pl)
WO (1) WO2005080382A1 (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557115C (en) * 2004-02-23 2012-10-02 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) * 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0512099D0 (en) 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
WO2007006117A1 (en) * 2005-07-13 2007-01-18 Nicogen Inc. Novel cyp2a6 inhibitors
US20070082940A1 (en) 2005-07-27 2007-04-12 Phil Skolnick Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
DE602006018152D1 (de) * 2005-08-22 2010-12-23 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3-rezeptoren
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
EA200870404A1 (ru) * 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
DE602007012531D1 (de) * 2006-04-03 2011-03-31 Glaxo Group Ltd Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
GB0607899D0 (en) 2006-04-03 2006-05-31 Glaxo Group Ltd Process for preparing heterocyclic derivatives
WO2007113260A1 (en) 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
GB0719234D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
CN102816106A (zh) 2008-06-24 2012-12-12 默沙东公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
AP3272A (en) 2008-09-22 2015-05-31 Cayman Chem Co Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases
CN102803224A (zh) 2009-06-26 2012-11-28 万能药生物有限公司 新的氮杂双环己烷类化合物
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160279098A1 (en) * 2013-11-11 2016-09-29 Euthymics Bioscience, Inc. Novel methods
EP3331886B1 (en) 2015-08-05 2020-07-15 Indivior UK Limited Dopamine d3 receptor antagonists having a bicyclo moiety
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
WO2021262587A1 (en) 2020-06-22 2021-12-30 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
JP2025501553A (ja) 2021-12-21 2025-01-22 コーセプト セラピューティクス， インコーポレイテッド 二環式インダゾールグルココルチコイド受容体拮抗薬
WO2023122600A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated Piperazine indazole glucocorticoid receptor antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI274750B (en) * 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
CZ20031311A3 (cs) * 2000-11-14 2004-04-14 Smithkline Beecham P. L. C. Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
SI1440059T1 (sl) 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
PL375256A1 (pl) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-Oksadiazole jako modulatory metabotropowegoreceptora-5 glutaminianergicznego
CA2557115C (en) * 2004-02-23 2012-10-02 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
DE602006018152D1 (de) * 2005-08-22 2010-12-23 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3-rezeptoren
EA200870404A1 (ru) 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0616574D0 (en) * 2006-08-21 2006-09-27 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CY1109854T1 (el) 2014-09-10
AR047890A1 (es) 2006-03-01
PT2070922E (pt) 2011-11-24
US7855298B2 (en) 2010-12-21
AU2009212887A1 (en) 2009-09-24
TW200538113A (en) 2005-12-01
CY1113029T1 (el) 2016-04-13
PL2060570T3 (pl) 2012-06-29
EP2060570A3 (en) 2009-06-03
EP1745040B1 (en) 2009-12-09
JP2007523208A (ja) 2007-08-16
PL1745040T3 (pl) 2010-05-31
JP4960217B2 (ja) 2012-06-27
US8263782B2 (en) 2012-09-11
NO20064309L (no) 2006-11-23
US20070142438A1 (en) 2007-06-21
CA2557115A1 (en) 2005-09-01
SI1745040T1 (sl) 2010-04-30
DK2060570T3 (da) 2012-04-30
ES2337590T3 (es) 2010-04-27
DK2070922T3 (da) 2011-11-28
BRPI0507945A (pt) 2007-07-24
CA2557115C (en) 2012-10-02
MA28438B1 (fr) 2007-02-01
WO2005080382A1 (en) 2005-09-01
DK1745040T3 (da) 2010-04-12
KR20060127991A (ko) 2006-12-13
HRP20120281T1 (hr) 2012-04-30
PT2060570E (pt) 2012-05-07
US20100160336A1 (en) 2010-06-24
HRP20100114T1 (hr) 2010-04-30
EP2070922A1 (en) 2009-06-17
SI2070922T1 (sl) 2011-12-30
ATE542816T1 (de) 2012-02-15
CN1946714B (zh) 2011-06-15
IL177184A0 (en) 2006-12-10
EP1745040A1 (en) 2007-01-24
ATE451364T1 (de) 2009-12-15
HK1103016A1 (en) 2007-12-14
EP2060570A2 (en) 2009-05-20
ATE520686T1 (de) 2011-09-15
RU2006133909A (ru) 2008-03-27
AU2005215918B2 (en) 2009-06-11
EP2070922B1 (en) 2011-08-17
CN1946714A (zh) 2007-04-11
EP1745040B9 (en) 2010-06-02
EP2060570B1 (en) 2012-01-25
SI2060570T1 (sl) 2012-05-31
PE20051173A1 (es) 2006-02-14
DE602005018190D1 (de) 2010-01-21
KR101143718B1 (ko) 2012-07-05
RU2434011C2 (ru) 2011-11-20
AU2005215918C1 (en) 2010-01-21
US8283474B2 (en) 2012-10-09
ES2380990T3 (es) 2012-05-22
CY1112011T1 (el) 2015-11-04
AU2005215918A1 (en) 2005-09-01
US20100152195A1 (en) 2010-06-17
PT1745040E (pt) 2010-03-08
HRP20110781T1 (hr) 2011-11-30

Similar Documents

Publication Publication Date Title
IL177184A0 (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
IL194385A0 (en) Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
IL192327A0 (en) Modulators of muscarinic receptors
AP2439A (en) 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
TWI366458B (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
ZA200701397B (en) Modulators of muscarinic receptors
IL196976A0 (en) Use of azabicyclo hexane derivatives
IL191602A0 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
AP2006003849A0 (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
IL174419A0 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
AP2006003787A0 (en) 3-(4-Heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
AU2003205964A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ZA200606661B (en) Modulation of peroxisome proliferation-activated receptors
AU2003214520A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ZA200606221B (en) Azabicyclo (3.1.0) Hexane derivatives useful as modulators of Dopamine D3 Receptors
ZA200804438B (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
HK1116680A (en) Use of azabicyclo hexane derivatives
HK1106520A (en) Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
HK1120194A (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
HK1102756A (en) Modulators of muscarinic receptors
ZA200508200B (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
HK1109895A (en) 1,2-dihydro-spiro(3h-indole-3-4 -piperidine) compounds as modulators of the mas receptor novel
HK1109890A (en) Pyrrolinidium derivatives as m3 muscarinic receptors